Abstract:The coronavirus disease 2019 (COVID-19) pandemic caused extensive loss of life worldwide. Further, the COVID-19 and influenza mix-infection had caused great distress to the diagnosis of the disease. To control illness progression and limit viral spread within the population, a real-time reverse-transcription PCR (RT-PCR) assay for early diagnosis of COVID-19 was developed, but detection was time-consuming (4-6 h). To improve the diagnosis of COVID-19 and influenza, we herein developed a recombinase polymerase amplification (RPA) method for simple and rapid amplification of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 and Influenza A (H1N1, H3N2) and B (influenza B). Genes encoding the matrix protein (M) for H1N1, and the hemagglutinin (HA) for H3N2, and the polymerase A (PA) for Influenza B, and the nucleocapsid protein (N), the RNA-dependent-RNA polymerase (RdRP) in the open reading frame 1ab (ORF1ab) region, and the envelope protein (E) for SARS-CoV-2 were selected, and specific primers were designed. We validated our method using SARS-CoV-2, H1N1, H3N2 and influenza B plasmid standards and RNA samples extracted from COVID-19 and Influenza A/B (RT-PCR-verified) positive patients. The method could detect SARS-CoV-2 plasmid standard DNA quantitatively between 10(2) and 10(5) copies/ml with a log linearity of 0.99 in 22 min. And this method also be very effective in simultaneous detection of H1N1, H3N2 and influenza B. Clinical validation of 100 cases revealed a sensitivity of 100% for differentiating COVID-19 patients from healthy controls when the specificity was set at 90%. These results demonstrate that this nucleic acid testing method is advantageous compared with traditional PCR and other isothermal nucleic acid amplification methods in terms of time and portability. This method could potentially be used for detection of SARS-CoV-2, H1N1, H3N2 and influenza B, and adapted for point-of-care (POC) detection of a broad range of infectious pathogens in resource-limited settings.

Application of an In-Cell Western assay for measurement of influenza A virus replication.

Rapid Detection of Influenza A Viruses Using a Real-Time Reverse Transcription Recombinase-Aided Amplification Assay.

A Microfluidic Cell Chip for Virus Isolation Via Rapid Screening for Permissive Cells

Establishment of a High-Throughput Assay to Monitor Influenza A Virus RNA Transcription and Replication

A SYBR Green I real-time RT-PCR assay for detection and differentiation of influenza A(H1N1) virus in swine populations.

Novel, Real-Time Cell Analysis for Measuring Viral Cytopathogenesis and the Efficacy of Neutralizing Antibodies to the 2009 Influenza A (h1n1) Virus

Establishment of a rapid ELISPOT assay for influenza virus titration and neutralizing antibody detection

High-Throughput cell-based immunofluorescence assays against influenza

In-Cell Western Assays to Evaluate Hantaan Virus Replication As a Novel Approach to Screen Antiviral Molecules and Detect Neutralizing Antibody Titers

Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, influenza A and B

A Simple And Robust Approach For Evaluation Of Antivirals Using A Recombinant Influenza Virus Expressing Gaussia Luciferase

A cell-based screening system for influenza A viral RNA transcription/replication inhibitors

A practical and rapid screening method for influenza virus neuraminidase inhibitors based on fluorescence detection

An Overview of Influenza A Virus Detection Methods: From State-of-the-Art of Laboratories to Point-of-Care Strategies

Development and Comparison of Molecular Assays for the Rapid Detection of the Pandemic Influenza A (H1N1) 2009 Virus

Accurate detection of influenza A virus by use of a novel cross-priming isothermal amplification-based point-of-care assay

A rapid influenza diagnostic test based on detection of viral neuraminidase activity

Evaluation of a Novel Micro/nanofluidic Chip Platform for the Detection of Influenza A and B Virus in Patients with Influenza-Like Illness

Development of an HiBiT-tagged Reporter H3N2 Influenza A Virus and Its Utility As an Antiviral Screening Platform

Characterization Of Receptor Binding Profiles Of Influenza A Viruses Using An Ellipsometry-Based Label-Free Glycan Microarray Assay Platform

Sensitive and rapid detection of influenza A virus for disease surveillance using dual-probe electrochemical biosensor